Park C, Seo HW, Han K, Kang I, Chae C. Evaluation of the efficacy of a new modified live porcine
reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS)
against heterologous PRRSV challenge. Vet Microbiol. 2014 Aug 27;172(3-4):432-42. doi:
10.1016/j.vetmic.2014.05.030. Epub 2014 Jun 6.
Abstract
The
objective of this study was to evaluate a new modified live porcine
reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS,
Zoetis, Florham, NJ, USA) that was based on a virulent US PRRSV isolate (P129)
attenuated using CD163-expressing cell lines. Sixty-four PRRSV-seronegative
3-week-old pigs were randomly divided into the following four groups:
vaccinated challenged (group 1), vaccinated unchallenged (group 2),
unvaccinated challenged (group 3), and unvaccinated unchallenged (group 4). The
pigs in groups 1 and 2 were immunized with a 2.0 mL dose of modified live PRRSV
vaccine at 21 days of age, according to the manufacturer's recommendations. At
56 days of age (0 days post-challenge), the pigs in groups 1 and 3 were
inoculated intranasally with 3 mL of tissue culture fluid containing 10(5) 50%
tissue culture infective dose (TCID50)/mL of PRRSV (SNUVR090851 strain, fourth
passage in MARC-145 cells). Vaccinated challenged pigs exhibited significantly
lower (P<0.05) respiratory scores, viremia, macroscopic and microscopic lung
lesion scores, and PRRSV-antigen with interstitial pneumonia than unvaccinated
challenged pigs. The induction of PRRSV-specific IFN-γ-SCs by the new modified
live PRRSV vaccine produced a protective immune response, leading to the
reduction of PRRSV viremia. Although the new modified live PRRSV vaccine is not
effective against heterologous PRRSV challenge, the new modified live PRRSV
vaccine was able to reduce the levels of viremia and nasal shedding, and
severity of PRRSV-induced lesions after challenging virus under experimental
conditions.
Copyright
© 2014 Elsevier B.V. All rights reserved.
KEYWORDS:
Modified live PRRSV
vaccine; Porcine reproductive and respiratory syndrome virus; Respiratory
disease; Vaccine efficacy
PMID:
24970363 [PubMed - indexed for MEDLINE]
No comments:
Post a Comment